protein
| CSTF1 and repressing nuclear mRNA polyadenylation (linking mRNA 3' end formation to DNA damage and tumor suppression) |
|
RNA polymerase II holoenzyme |
|
BRCA1 for mediating of protein ubiquitination |
|
interaction with TP53( TP53 dependent role in apoptosis) |
|
UBXN1 associates with autoubiquitinated BRCA1/BARD1 heterodimers in a bipartite manner (interaction between NR5A1 and BRCA1/BARD1 may recruit BRCA1/BARD1 complex to the aromatase PII promoter for BRCA1/BARD1-mediate transcriptional repression) |
|
BRCA1/BARD1 complex interacts with NR5A1 |
|
BRCA1 functions depend on the interaction with BARD1 for its stability, nuclear localization and ubiquitin ligase activity |
|
BRCA1 heterodimerizes with its partner protein, BARD1, via the RING domain present in both proteins |
|
BRCA1 and BARD1 might have common as well as separate functions |
|
both BRCA1 and BARD1 bind DNA and interact with RAD51, and BRCA1-BARD1 enhances the recombinase activity of RAD51 |
|
OLA1-BARD1 interaction is important for the regulation of centrosome number |
|
regulation of BRCA1-BARD1 heterodimerization through SIRT2 deacetylation, elucidating a critical upstream signaling event directing BRCA1-BARD1 heterodimerization, which facilitates HR and tumor suppression |
|
novel function of the BRCA1-BARD1 complex in the regulation of TOP2B and Pol II-mediated gene expression |
|
BARD1 BRCT domain serves as an ATPase activating protein to control OLA1 allosterically |
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
tumoral
| germinal mutation
|  
|  
|  
|
in breast and breast-ovarian cancers | tumoral
|  
| deletion
|  
|  
|
homozygous deletion, in basal breast cancer | tumoral
| germinal mutation
|  
|  
| loss of function
|
in patients with primary ovarian, fallopian tube, or peritoneal cancers | |